Foresee Pharmaceuticals Statistics

Total Valuation

Foresee Pharmaceuticals has a market cap or net worth of TWD 11.75 billion. The enterprise value is 11.40 billion.

Market Cap	11.75B
Enterprise Value	11.40B

Important Dates

The next estimated earnings date is Monday, February 24, 2025.

Earnings Date	Feb 24, 2025
Ex-Dividend Date	n/a

Share Statistics

Foresee Pharmaceuticals has 154.78 million shares outstanding. The number of shares has increased by 10.81% in one year.

Current Share Class	n/a
Shares Outstanding	154.78M
Shares Change (YoY)	+10.81%
Shares Change (QoQ)	+0.60%
Owned by Insiders (%)	2.67%
Owned by Institutions (%)	2.39%
Float	126.94M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	29.81
PB Ratio	14.74
P/TBV Ratio	19.98
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-12.25
EV / Sales	32.89
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-11.51

Financial Position

The company has a current ratio of 1.88, with a Debt / Equity ratio of 0.52.

Current Ratio	1.88
Quick Ratio	1.34
Debt / Equity	0.52
Debt / EBITDA	n/a
Debt / FCF	-0.37
Interest Coverage	-155.71

Financial Efficiency

Return on equity (ROE) is -81.68% and return on invested capital (ROIC) is -41.01%.

Return on Equity (ROE)	-81.68%
Return on Assets (ROA)	-31.81%
Return on Capital (ROIC)	-41.01%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.19
Inventory Turnover	1.35

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -16.02% in the last 52 weeks. The beta is 1.11, so Foresee Pharmaceuticals's price volatility has been higher than the market average.

Beta (5Y)	1.11
52-Week Price Change	-16.02%
50-Day Moving Average	77.15
200-Day Moving Average	85.87
Relative Strength Index (RSI)	48.45
Average Volume (20 Days)	262,116

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Foresee Pharmaceuticals had revenue of TWD 346.56 million and -930.72 million in losses. Loss per share was -6.84.

Revenue	346.56M
Gross Profit	154.16M
Operating Income	-910.11M
Pretax Income	-885.83M
Net Income	-930.72M
EBITDA	-846.95M
EBIT	-910.11M
Loss Per Share	-6.84

Full Income Statement

Balance Sheet

The company has 714.81 million in cash and 364.47 million in debt, giving a net cash position of 350.34 million or 2.26 per share.

Cash & Cash Equivalents	714.81M
Total Debt	364.47M
Net Cash	350.34M
Net Cash Per Share	2.26
Equity (Book Value)	704.10M
Book Value Per Share	5.15
Working Capital	517.57M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -821.72 million and capital expenditures -168.20 million, giving a free cash flow of -989.92 million.

Operating Cash Flow	-821.72M
Capital Expenditures	-168.20M
Free Cash Flow	-989.92M
FCF Per Share	-6.40

Full Cash Flow Statement

Margins

Gross margin is 44.48%, with operating and profit margins of -262.61% and -268.56%.

Gross Margin	44.48%
Operating Margin	-262.61%
Pretax Margin	-255.60%
Profit Margin	-268.56%
EBITDA Margin	-244.38%
EBIT Margin	-262.61%
FCF Margin	n/a

Dividends & Yields

Foresee Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.81%
Shareholder Yield	-10.81%
Earnings Yield	-9.01%
FCF Yield	-8.43%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Foresee Pharmaceuticals has an Altman Z-Score of 3.15.

Altman Z-Score	3.15
Piotroski F-Score	n/a